

# CITATION REPORT

List of articles citing

Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries

DOI: 10.1161/01.CIR.94.7.1690  
Circulation, 1996, 94, 1690-7.

**Source:** <https://exaly.com/paper-pdf/86225397/citation-report.pdf>

**Version:** 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
656	Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model. <b>1997</b> , 29, 808-16		233
655	Histologic Consequences of Endoluminal Coronary Artery Hydrogel Polymer Paving. <b>1997</b> , 3, 315-316		
654	Novel stents for the prevention of restenosis. <b>1997</b> , 7, 245-9		8
653	Effect on intimal hyperplasia of dexamethasone released from coated metal stents compared with non-coated stents in canine femoral arteries. <b>1998</b> , 21, 487-96		47
652	Polyurethane-coated Dacron-covered stent-grafts for TIPS: results in swine. <b>1998</b> , 21, 497-500		25
651	The Challenges of Today's Endovascular Interventions. <b>1998</b> , 11, S1-S8		
650	Biocompatibility of polyurethane-coated stents: tissue and vascular aspects. <b>1998</b> , 45, 202-7		52
649	Materials and biomaterials for interventional radiology. <i>Biomedicine and Pharmacotherapy</i> , <b>1998</b> , 52, 76-88	7.5	6
648	In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. <b>1998</b> , 31, 224-30		578
647	Fibrin-film stenting in a porcine coronary injury model: efficacy and safety compared with uncoated stents. <b>1998</b> , 31, 1434-8		25
646	Biocompatibility aspects of new stent technology. <b>1998</b> , 32, 562-71		148
645	Intramural delivery of a specific tyrosine kinase inhibitor with biodegradable stent suppresses the restenotic changes of the coronary artery in pigs in vivo. <b>1998</b> , 32, 780-6		115
644	Current biotechnological approaches to the prevention of restenosis. <b>1998</b> , 9, 375-88		2
643	The stent decade: 1987 to 1997. Stanford Stent Summit faculty. <b>1998</b> , 136, 578-99		57
642	Tissue response to covered Wallstents. <b>1998</b> , 9, 471-8		44
641	Dealing with in-stent restenosis. <b>1998</b> , 79, 319-23		23
640	Phosphorylcholine-coated metallic stents in rabbit iliac and porcine coronary arteries. <b>1998</b> , 32, 261-8		33

639	Valves in development for autogenous tissue valve replacement. <b>1999</b> , 2, 51-64		11
638	In vivo biocompatibility and degradation studies of polyhydroxyoctanoate in the rat: a new sealant for the polyester arterial prosthesis. <b>1999</b> , 5, 369-86		31
637	Biomedical application of functional polymers. <b>1999</b> , 39, 99-138		225
636	A Biodegradable Poly-l-lactic Acid Coronary Stent in the Porcine Coronary Artery. <b>1999</b> , 12, 443-450		59
635	Intracellular depolymerase activity in isolated inclusion bodies containing polyhydroxyalkanoates with long alkyl and functional substituents in the side chain. <b>1999</b> , 26, 187-92		21
634	Porous and nonporous polycarbonate urethane stent-grafts for TIPS formation: biologic responses. <b>1999</b> , 10, 1255-63		18
633	Gene therapy and vascular disease. <b>1999</b> , 46, 85-150		12
632	Use of nitric-oxide-eluting polymer-coated coronary stents for prevention of restenosis in pigs. <i>Coronary Artery Disease</i> , <b>2000</b> , 11, 351-7	1.4	24
631	Radiolabeling brachytherapy sources with Re-188 through chelating microfilms: stents. <b>2000</b> , 53, 244-51		3
630	New biocompatible polymer surface coating for stents results in a low neointimal response. <b>2000</b> , 52, 193-8		24
629	Gene delivery from a DNA controlled-release stent in porcine coronary arteries. <b>2000</b> , 18, 1181-4		204
628	Experimental and Clinical Studies of Biodegradable Polymeric Stents. <b>2000</b> , 13, 439-445		3
627	Evaluation of fluorinated polymers as coronary stent coating. <b>2000</b> , 11, 207-12		14
626	Antithrombotic Therapy during and after Intracoronary Stenting. <b>2000</b> , 16, 185-196		
625	Local drug delivery: an emerging approach in the treatment of restenosis. <b>2000</b> , 5, 97-102		24
624	Biocompatibility of phosphorylcholine coated stents in normal porcine coronary arteries. <b>2000</b> , 83, 338-45		183
623	Stents covered by autologous venous grafts: feasibility and immediate and long-term results. <b>2000</b> , 139, 437-45		24
622	Neointimal thickening after stent delivery of paclitaxel: change in composition and arrest of growth over six months. <b>2000</b> , 36, 2325-32		242

621	Polymeric-based perivascular delivery of a nitric oxide donor inhibits intimal thickening after balloon denudation arterial injury: role of nuclear factor-kappaB. <b>2000</b> , 35, 493-501		64
620	The polytetrafluoroethylene-covered stent: a device with multiple potential advantages. <b>2001</b> , 4, 145-149		7
619	A novel approach to temporary stenting: degradable cardiovascular stents produced from corrodible metal-results 6-18 months after implantation into New Zealand white rabbits. <b>2001</b> , 86, 563-9		381
618	Laser cutting: influence on morphological and physicochemical properties of polyhydroxybutyrate. <b>2001</b> , 22, 2447-52		31
617	Development of high-performance stent: gelatinous photogel-coated stent that permits drug delivery and gene transfer. <b>2001</b> , 57, 559-66		69
616	Phosphorylcholine-based polymer coatings for stent drug delivery. <b>2001</b> , 12, 865-70		39
615	Therapeutic applications of viscous and injectable poly(ortho esters). <b>2001</b> , 53, 45-73		48
614	Stent development and local drug delivery. <b>2001</b> , 59, 227-48		123
613	Development of a platform to evaluate and limit in-stent restenosis. <b>2002</b> , 8, 395-407		9
612	Stents: material, surface texture and design, in theory and practice. <b>2002</b> , 11, 157-63		3
611	In-vivo biocompatibility evaluation of stents coated with a new biodegradable elastomeric and functional polymer. <i>Coronary Artery Disease</i> , <b>2002</b> , 13, 237-41	1.4	61
610	Twenty-eight-day efficacy and phamacokinetics of the sirolimus-eluting stent. <i>Coronary Artery Disease</i> , <b>2002</b> , 13, 183-8	1.4	132
609	Can we prevent in-stent restenosis?. <b>2002</b> , 17, 518-25		21
608	Heparin-coated versus uncoated Palmaz-Schatz stent in native coronary circulation. A randomized study with blind angioscopic assessment. <b>2002</b> , 25, 461-9		5
607	Maintenance of a functional endothelial cell monolayer on a fibroblast/polymer substrate under physiologically relevant shear stress conditions. <b>2002</b> , 8, 695-708		27
606	Coronary in-stent restenosis: current status and future strategies. <b>2002</b> , 39, 183-93		279
605	Controlled Release Technology. <b>2002</b> ,		3
604	A tissue-engineered stent for cell-based vascular gene transfer. <b>2002</b> , 13, 433-41		28

603	Gene delivery to pig coronary arteries from stents carrying antibody-tethered adenovirus. <b>2002</b> , 13, 443-54	87
602	Bio-Absorbable Stents: Technology and Applications. <b>2002</b> , 13, P265-P268	
601	Polymerized degradable hyaluronan--a platform for stent coating with inherent inhibitory effects on neointimal formation in a porcine coronary model. <b>2002</b> , 25, 1166-73	20
600	Drug-eluting stents: from bench to bed. <b>2002</b> , 3, 226-41	28
599	New stent design for autologous venous graft-covered stent preparation: first human application for sealing of a coronary aneurysm. <b>2002</b> , 55, 222-7	18
598	Stenting very small coronary narrowings (2002, 55, 303-8	28
597	Coronary artery stents: evaluating new designs for contemporary percutaneous intervention. <b>2002</b> , 56, 562-76	22
596	Long-term stability of a coronary stent coating post-implantation. <b>2002</b> , 63, 699-705	43
595	Analysis of a phosphorylcholine-based polymer coating on a coronary stent pre- and post-implantation. <b>2002</b> , 23, 1697-706	190
594	Drug-eluting stents for cardiovascular disorders. <b>2003</b> , 5, 308-16	13
593	Intense inflammatory reaction to heparin polymer coated intravascular Palmaz stents in porcine arteries compared to uncoated Palmaz stents. <b>2003</b> , 26, 158-67	9
592	Platelet responses and coagulation activation on polylactide and heparin-polycaprolactone-L-lactide-coated polylactide stent struts. <b>2003</b> , 67, 785-91	12
591	Fabrication of micropored elastomeric film-covered stents and acute-phase performances. <b>2003</b> , 64, 52-61	23
590	Study of antirestenosis with the BiodivYsio dexamethasone-eluting stent (STRIDE): a first-in-human multicenter pilot trial. <b>2003</b> , 60, 172-8; discussion 179	76
589	In vitro hemocompatibility studies of drug-loaded poly-(L-lactic acid) fibers. <b>2003</b> , 24, 5191-201	46
588	Polymer micelle-like aggregates of novel amphiphilic biodegradable poly(asparagine) grafted with poly(caprolactone). <b>2003</b> , 44, 583-591	76
587	Characterization of the thrombogenic potential of surface oxides on stainless steel for implant purposes. <b>2003</b> , 219, 347-362	26
586	Transgene delivery of plasmid DNA to smooth muscle cells and macrophages from a biostable polymer-coated stent. <b>2003</b> , 10, 1471-8	50

585	Future Direction with Drug Delivery and Stent Design. <b>2003</b> , 14, P86-P91		
584	Addition of paclitaxel to contrast media prevents restenosis after coronary stent implantation. <b>2003</b> , 42, 1415-20		116
583	Biocorrosion of magnesium alloys: a new principle in cardiovascular implant technology?. <b>2003</b> , 89, 651-6		584
582	Bioactive coatings of endovascular stents based on polyelectrolyte multilayers. <b>2003</b> , 4, 1564-71		280
581	In vivo evaluation of a new bioabsorbable self-expanding biliary stent. <b>2003</b> , 58, 777-84		63
580	Drug delivery systems for stents. <b>2003</b> , 1, 157-170		1
579	Local methylprednisolone delivery using a BiodivYsio phosphorylcholine-coated drug-delivery stent reduces inflammation and neointimal hyperplasia in a porcine coronary stent model. <b>2003</b> , 5, 166-71		12
578	Requirements for quantitative analysis of intimal reaction in arteries treated with intraluminal stents. <i>Journal of Endovascular Therapy</i> , <b>2003</b> , 10, 1110-6	2.5	4
577	Bioresorbable polymeric stents: current status and future promise. <b>2003</b> , 14, 299-312		64
576	A critical role for elastin signaling in vascular morphogenesis and disease. <b>2003</b> , 130, 411-23		329
575	Serial intravascular ultrasonographic measurements after implantation of biodegradable polymer-coated stents in porcine coronary arteries. <i>Coronary Artery Disease</i> , <b>2003</b> , 14, 409-12	1.4	3
574	Addition of cytochalasin D to a biocompatible oil stent coating inhibits intimal hyperplasia in a porcine coronary model. <i>Coronary Artery Disease</i> , <b>2003</b> , 14, 545-55	1.4	2
573	Long-term biocompatibility evaluation of a novel polymer-coated stent in a porcine coronary stent model. <i>Coronary Artery Disease</i> , <b>2003</b> , 14, 401-8	1.4	16
572	[Prevention of in-stent restenosis: towards an in situ treatment?]. <b>2004</b> , 20, 98-104		3
571	Sirolimus- or paclitaxel-eluting stents to prevent coronary artery restenosis. <b>2004</b> , 5, 2209-20		8
570	In-stent restenosis limitation with stent-based controlled-release nitric oxide: initial results in rabbits. <b>2004</b> , 230, 377-82		32
569	Early experiences and clinical implications of drug-eluting stents: part 1. <b>2004</b> , 38, 661-9		11
568	Why coat a stent with polymer?. <b>2004</b> , 230, 1-2		2

567	Clinical trials in restenosis with 7-hexanoyltaxol and paclitaxel-eluting stents. <b>2004</b> , 2, 745-52	
566	Histopathologic evaluation of a novel-design nitinol stent: the Biflex stent. <b>2004</b> , 6, 13-9	8
565	Methotrexate loaded SAE coated coronary stents reduce neointimal hyperplasia in a porcine coronary model. <b>2004</b> , 90, 195-9	16
564	Biodegradable self-expanding poly-L/D-lactic acid vascular stent: a pilot study in canine and porcine iliac arteries. <i>Journal of Endovascular Therapy</i> , <b>2004</b> , 11, 712-8	2.5 34
563	Drug-eluting bioabsorbable magnesium stent. <b>2004</b> , 17, 391-5	34 <sup>o</sup>
562	[Drug-coated stents. Where do we stand in 2004?]. <b>2004</b> , 93, 646-8	1
561	Neointima formation on vascular elastic laminae and collagen matrices scaffolds implanted in the rat aortae. <b>2004</b> , 25, 1869-82	36
560	Assessment of subacute inflammatory and proliferative response to coronary stenting in a porcine model by local gene expression studies and histomorphometry. <b>2004</b> , 25, 957-63	12
559	Phospholipid based polymer as drug release coating for cardiovascular device. <b>2004</b> , 40, 291-298	24
558	About the methods of preparation of poly(ethylene oxide)-b-poly(ε-caprolactone) nanoparticles in water. <b>2004</b> , 242, 203-211	82
557	Coronary aneurysm after implantation of a paclitaxel-eluting stent. <b>2004</b> , 38, 349-52	26
556	Biologic response to polymer-coated stents: in vitro analysis and results in an iliac artery sheep model. <b>2004</b> , 230, 151-62	35
555	Drug Delivery Systems. <b>2004</b> ,	
554	The influence of physical stent parameters upon restenosis. <b>2004</b> , 52, 196-205	82
553	Clinical impact of stent construction and design in percutaneous coronary intervention. <b>2004</b> , 147, 764-73	47
552	Effect of surface oxide properties on corrosion resistance of 316L stainless steel for biomedical applications. <b>2004</b> , 46, 427-441	184
551	A BioMEMS review: MEMS technology for physiologically integrated devices. <b>2004</b> , 92, 6-21	363
550	Effect of stent coating alone on in vitro vascular smooth muscle cell proliferation and apoptosis. <b>2004</b> , 286, H902-8	30

549	Initial and follow-up results of the BiodivYsio phosphorylcholine coated stent for treatment of coronary artery disease. <b>2005</b> , 69, 295-300		13
548	Impact of asymmetric stent expansion on neointimal hyperplasia following sirolimus-eluting stent implantation. <b>2005</b> , 96, 1404-7		12
547	Amorphous oxide--a platform for drug delivery. <b>2005</b> , 102, 539-49		5
546	Heparin-loaded zein microsphere film and hemocompatibility. <b>2005</b> , 105, 120-31		145
545	In vitro study of drug loading on polymer-free oxide films of metallic implants. <b>2005</b> , 75, 519-29		5
544	Evaluation of biodegradable synthetic scaffold coated on arterial prostheses implanted in rat subcutaneous tissue. <b>2005</b> , 26, 7387-401		30
543	Comparative study of tacrolimus and paclitaxel stent coating in the porcine coronary model. <b>2005</b> , 94, 445-52		21
542	Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture. <b>2005</b> , 85, 1-31		639
541	Granulation encapsulated stent: a new therapeutic approach for vascular implantation. <b>2007</b> , 93, 238-43		3
540	Drug-eluting biodegradable poly-D/L-lactic acid vascular stents: an experimental pilot study. <i>Journal of Endovascular Therapy</i> , <b>2005</b> , 12, 371-9	2.5	57
539	Curcumin impregnation improves the mechanical properties and reduces the inflammatory response associated with poly(L-lactic acid) fiber. <b>2005</b> , 16, 353-70		36
538	Negative regulation of monocyte adhesion to arterial elastic laminae by signal regulatory protein alpha and Src homology 2 domain-containing protein-tyrosine phosphatase-1. <b>2005</b> , 280, 39294-301		29
537	Very late thrombosis after implantation of sirolimus eluting stent. <b>2005</b> , 91, e45		27
536	Drug-eluting stents: results, promises and problems. <b>2005</b> , 99, 9-17		153
535	Short- and long-term outcomes of the titanium-NO stent registry. <b>2005</b> , 6, 2-6		27
534	Randomized comparison of carbon ion-implanted stent versus bare metal stent in coronary artery disease: the Asian Pacific Multicenter Arthos Stent Study (PASS) trial. <b>2005</b> , 149, 336-41		17
533	Technology Insight: an overview of research in drug-eluting stents. <b>2005</b> , 2, 647-58		43
532	Gender-based outcomes after paclitaxel-eluting stent implantation in patients with coronary artery disease. <b>2005</b> , 45, 1180-5		102



531	Vascular oligonucleotide transfer facilitated by a polymer-coated stent. <b>2005</b> , 16, 734-40	9
530	Drug loading of nanoporous TiO <sub>2</sub> films. <b>2006</b> , 1, L11-5	42
529	Progressive stent technologies: new approaches for the treatment of cardiovascular diseases. <b>2006</b> , 3, 783-97	8
528	Tissue Engineering of Cardiac Tissues. <b>2006</b> ,	
527	Biopolyesters in Tissue Engineering Applications. 1-61	53
526	Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. <b>2006</b> , 47, 175-81	514
525	Allergic reactions after the implantation of drug-eluting stents: is it the pill or the polymer?. <b>2006</b> , 47, 182-3	51
524	Sirolimus and Paclitaxel on polymer-based drug-eluting stents: similar but different. <b>2006</b> , 47, 708-14	134
523	Release of plasmid DNA from intravascular stents coated with ultrathin multilayered polyelectrolyte films. <b>2006</b> , 7, 2483-91	144
522	In situ visualization of paclitaxel distribution and release by coherent anti-Stokes Raman scattering microscopy. <b>2006</b> , 78, 8036-43	59
521	The favorable clinical and angiographic outcomes of a high-dose dexamethasone-eluting stent: randomized controlled prospective study. <b>2006</b> , 152, 887.e1-7	17
520	Biomaterials surface characterization and modification. <b>2006</b> , 29, 824-33	14
519	The paclitaxel-eluting stent in percutaneous coronary intervention: part I: background and clinical comparison to bare metal stents. <b>2006</b> , 14, 88-98	10
518	Polymers, drug release, and drug-eluting stents. <b>2006</b> , 19, 500-6	80
517	Transplantable retinal pigment epithelial cell sheets for tissue engineering. <b>2006</b> , 27, 3639-44	29
516	Reduction of the in vitro pro-inflammatory response by macrophages to poly(3-hydroxybutyrate-co-3-hydroxyvalerate). <b>2006</b> , 27, 4715-25	31
515	Long-term biocompatibility of a corrodible peripheral iron stent in the porcine descending aorta. <b>2006</b> , 27, 4955-62	390
514	Reduced thrombogenicity of nitinol stents--in vitro evaluation of different surface modifications and coatings. <b>2006</b> , 27, 643-50	105

513	Role of stent design and coatings on restenosis and thrombosis. <b>2006</b> , 58, 377-86		138
512	Mechanismen der arteriellen Restenose und Therapieansätze zur Prävention. <b>2006</b> , 11, 347-355		1
511	The road to bioabsorbable stents: reaching clinical reality?. <b>2006</b> , 29, 11-6		171
510	Angiographic pattern of restenosis following implantation of overlapping sirolimus-eluting (Cypher) stents. <b>2006</b> , 97, 499-501		8
509	Polymer-based paclitaxel-eluting stents are superior to nonpolymer-based paclitaxel-eluting stents in the treatment of de novo coronary lesions. <b>2006</b> , 98, 1022-7		26
508	Drug-eluting coronary stents. <b>2006</b> , 31, 8-119		41
507	Paclitaxel releasing films consisting of poly(vinyl alcohol)-graft-poly(lactide-co-glycolide) and their potential as biodegradable stent coatings. <b>2006</b> , 111, 235-46		119
506	Eosinophilic tissue response several weeks after sirolimus-eluting Cypher stent implantation within a bare metal stent in a coronary saphenous vein graft. <b>2006</b> , 67, 38-40		6
505	Safety and efficacy of bioabsorbable magnesium alloy stents in porcine coronary arteries. <b>2006</b> , 68, 607-17; discussion 618-9		254
504	Surface modification of metallic cardiovascular stents by strongly adhering aliphatic polyester coatings. <b>2006</b> , 76, 521-9		13
503	PLA stereocopolymers as sources of bioresorbable stents: preliminary investigation in rabbit. <b>2006</b> , 77, 349-56		21
502	Stent-based tempamine delivery on neointimal formation in a porcine coronary model. <b>2006</b> , 8, 210-6		12
501	Effects of hydrolysis on a new biodegradable co-polymer. <b>2006</b> , 17, 615-30		28
500	Paradoxical effects of aurintricarboxylic acid and RG-13577: acute thrombosis and in-stent stenosis in a passive-coated stent. <i>Journal of Endovascular Therapy</i> , <b>2006</b> , 13, 94-103	2.5	2
499	Update on drug-eluting stents for prevention of restenosis. <b>2006</b> , 14, 75-82		4
498	Iliac anastomotic stenting with a biodegradable poly-L-lactide stent: a preliminary study after 1 and 6 weeks. <i>Journal of Endovascular Therapy</i> , <b>2006</b> , 13, 539-48	2.5	16
497	Iliac anastomotic stenting with a sirolimus-eluting biodegradable poly-L-lactide stent: a preliminary study after 6 weeks. <i>Journal of Endovascular Therapy</i> , <b>2006</b> , 13, 630-9	2.5	28
496	The future of drug eluting stents. <b>2006</b> , 92, 585-8		16

495	Are resorbable implants about to become a reality?. <b>2006</b> , 16, 107-16		80
494	Paclitaxel delivered to adventitia attenuates neointima formation without compromising re-endothelialization after angioplasty in a porcine restenosis model. <i>Journal of Endovascular Therapy</i> , <b>2006</b> , 13, 616-29	2.5	23
493	First absorbable metal stent implantation in human coronary arteries. <b>2006</b> , 4, 128-30		10
492	Electrospinning versus knitting: two scaffolds for tissue engineering of the aortic valve. <b>2006</b> , 17, 77-89		80
491	BioMatrix Biolimus A9-eluting coronary stent: a next-generation drug-eluting stent for coronary artery disease. <b>2006</b> , 3, 731-41		79
490	Bisphosphonate-mediated gene vector delivery from the metal surfaces of stents. <b>2006</b> , 103, 159-64		85
489	Haemocompatibility of vitamin-E-enriched poly(D,L-lactic acid). <b>2007</b> , 18, 785-97		7
488	Prevention of restenosis: is angioplasty the answer?. <b>2007</b> , 93, 539-41		30
487	Polymers as replacement materials for heart valves and arteries. <b>2007</b> , 111-140		3
486	Control of Degradation of Biocompatible Magnesium in a Pseudo-Physiological Environment by a Ceramic Like Anodized Coating. <b>2007</b> , 29-30, 95-98		17
485	Systemic application of anti-ICAM-1 monoclonal antibodies to prevent restenosis in rabbits: an anti-inflammatory strategy. <i>Coronary Artery Disease</i> , <b>2007</b> , 18, 117-23	1.4	9
484	Drug-eluting stents: preventing restenosis. <b>2007</b> , 15, 1-12		31
483	The efficacy of nanoscale poly[bis(trifluoroethoxy) phosphazene] (PTFEP) coatings in reducing thrombogenicity and late in-stent stenosis in a porcine coronary artery model. <b>2007</b> , 42, 303-11		32
482	Reduction of stenosis due to intimal hyperplasia after stent supported angioplasty of peripheral arteries by local administration of paclitaxel in swine. <b>2007</b> , 42, 579-85		48
481	Sirolimus-eluting biodegradable poly-L-lactide stent for peripheral vascular application: a preliminary study in porcine carotid arteries. <b>2007</b> , 139, 77-82		43
480	Dose-dependent coronary artery intimal thickening after local delivery of the anti-oxidant tetradecylthioacetic acid from stents. <b>2007</b> , 195, e39-47		4
479	In Vitro and In Vivo Biocompatibility Testing of Absorbable Metal Stents. <b>2007</b> , 253, 103-108		33
478	Evaluation of three polytetrafluoroethylene stent-grafts in a model of neointimal hyperplasia. <b>2007</b> , 18, 527-34		33

477	Delivery of large biopharmaceuticals from cardiovascular stents: a review. <b>2007</b> , 8, 3281-93	60
476	The next generation of drug-eluting stents: what's on the horizon?. <b>2007</b> , 7, 81-93	14
475	Drug-eluting stent technologies for vascular regeneration. <b>2007</b> , 98, 637-642	5
474	Drug delivery via nano-, micro and macroporous coronary stent surfaces. <b>2007</b> , 4, 287-95	44
473	Nanoscale eluting coatings based on alginate/chitosan hydrogels. <b>2007</b> , 2, 95-104	13
472	The Effect of a New Carbon Stent for Preventing Restenosis-Pro prospective, Randomized Study for Preventing Metal Allergy. <b>2007</b> , 37, 258	
471	First-in-human implantation of a fully bioabsorbable drug-eluting stent: the BVS poly-L-lactic acid everolimus-eluting coronary stent. <b>2007</b> , 69, 128-31	105
470	Treatment of drug-eluting stent restenosis with the same versus different drug-eluting stent. <b>2007</b> , 70, 9-14	45
469	A Possible Biodegradable Magnesium Implant Material. <b>2007</b> , 9, 298-302	375
468	Fabrication and in vitro characterization of three-dimensional organic/inorganic scaffolds by robocasting. <b>2007</b> , 83, 434-45	101
467	In-vitro assays of polymer-coated stents eluting platelet glycoprotein IIb/IIIa receptor monoclonal antibody. <b>2007</b> , 83, 861-7	10
466	Cellular behavior of neointima-like cells onto vitamin E-enriched poly(D,L)lactic acid. <b>2007</b> , 24, 307-12	5
465	Vascular delivery of c-myc antisense from cationically modified phosphorylcholine coated stents. <b>2007</b> , 28, 1218-24	14
464	Outcomes of CPR in the presence of partial occlusion of left anterior descending coronary artery. <b>2007</b> , 75, 357-65	15
463	Coronary stents, hypersensitivity reactions, and the Kounis syndrome. <b>2007</b> , 20, 314-23	64
462	Early vascular response to overlapped paclitaxel-eluting stents in swine coronary arteries. <b>2007</b> , 8, 251-8	13
461	Intravascular ultrasound comparison of sirolimus-eluting stent versus bare metal stent implantation in diseased saphenous vein grafts (from the RRISC [Reduction of Restenosis In Saphenous Vein Grafts With Cypher Sirolimus-Eluting Stent] trial). <b>2007</b> , 100, 52-8	16
460	Design criteria for the ideal drug-eluting stent. <b>2007</b> , 100, 3M-9M	64

459	Poly(ethylene carbonate): a thermoelastic and biodegradable biomaterial for drug eluting stent coatings?. <b>2007</b> , 117, 312-21		44
458	Release profiles in drug-eluting stents: issues and uncertainties. <b>2007</b> , 120, 149-60		139
457	Coronary stents: a materials perspective. <b>2007</b> , 28, 1689-710		630
456	Unconstrained recovery characterization of shape-memory polymer networks for cardiovascular applications. <b>2007</b> , 28, 2255-63		481
455	Immobilization of paracetamol and benzocaine pro-drug derivatives as long-range self-organized monolayers on graphite. <b>2008</b> , 63, 153-8		12
454	Temporäre Implantate für die endovaskuläre Applikation. <b>2008</b> , 13, 99-106		1
453	Short- and long-term effects of a novel paclitaxel coated stent in the porcine coronary model. <i>Clinical Research in Cardiology</i> , <b>2008</b> , 97, 118-23	6.1	11
452	Two year follow-up after treatment of coronary in-stent restenosis with a paclitaxel-coated balloon catheter. <i>Clinical Research in Cardiology</i> , <b>2008</b> , 97, 773-81	6.1	195
451	Comparison of a polymer-free rapamycin-eluting stent (YUKON) with a polymer-based paclitaxel-eluting stent (TAXUS) in real-world coronary artery lesions. <b>2008</b> , 71, 333-9		22
450	Long-term clinical, angiographic, and intravascular ultrasound outcomes of biodegradable polymer-coated sirolimus-eluting stents. <b>2008</b> , 72, 177-83		21
449	Novel bioabsorbable salicylate-based polymer as a drug-eluting stent coating. <b>2008</b> , 72, 186-94		55
448	Biodegradable polymers--are they the answer to late stent thrombosis? Too early to tell. <b>2008</b> , 72, 184-5		
447	Coronary artery aneurysms after drug-eluting stent implantation. <b>2008</b> , 1, 14-21		138
446	Implanted cardiovascular polymers: Natural, synthetic and bio-inspired. <b>2008</b> , 33, 853-874		183
445	Small-diameter biodegradable scaffolds for functional vascular tissue engineering in the mouse model. <b>2008</b> , 29, 1454-63		146
444	Biostability and biological performance of a PDMS-based polyurethane for controlled drug release. <b>2008</b> , 29, 2987-95		95
443	Reduced acute inflammatory responses to microgel conformal coatings. <b>2008</b> , 29, 4605-15		94
442	Controlled release from multilayer silk biomaterial coatings to modulate vascular cell responses. <b>2008</b> , 29, 894-903		97

441	Hypersensitivity reactions associated with endovascular devices. <b>2008</b> , 59, 7-22	101
440	Short-term effects of biocorrosible iron stents in porcine coronary arteries. <b>2008</b> , 21, 15-20	187
439	Vascular brachytherapy for patients with drug-eluting stent restenosis. <b>2008</b> , 21, 528-34	12
438	Contact angle, WAXS, and SAXS analysis of poly(beta-hydroxybutyrate) and poly(ethylene glycol) block copolymers obtained via <i>Azotobacter vinelandii</i> UWD. <b>2005</b> , 21, 959-64	26
437	Development of a composite degradable/nondegradable tissue-engineered vascular graft. <b>2008</b> , 32, 800-9	39
436	Optical coherence tomography and intravascular ultrasound imaging of bioabsorbable magnesium stent degradation in porcine coronary arteries. <b>2008</b> , 9, 248-54	56
435	Coronary artery aneurysm formation after drug-eluting stent implantation. <b>2008</b> , 9, 284-7	11
434	The future of drug-eluting stents. <b>2008</b> , 57, 171-80	97
433	Fully biodegradable coronary stents : progress to date. <b>2008</b> , 8, 305-14	65
432	Introducing the first polymer-free leflunomide eluting stent. <b>2008</b> , 200, 126-34	21
431	Drug-eluting stents - what should be improved?. <b>2008</b> , 40, 242-52	36
430	Efficacy of a polyphosphazene nanocoat in reducing thrombogenicity, in-stent stenosis, and inflammatory response in porcine renal and iliac artery stents. <b>2008</b> , 19, 427-37	18
429	Biocompatibility: meeting a key functional requirement of next-generation medical devices. <b>2008</b> , 36, 70-80	95
428	Inhibition of restenosis formation without compromising reendothelialization as a potential solution to thrombosis following angioplasty?. <b>2008</b> , 15, 85-92	10
427	Randomized trial of three rapamycin-eluting stents with different coating strategies for the reduction of coronary restenosis. <b>2008</b> , 29, 1975-82	158
426	A review of the development of a vehicle for localized and controlled drug delivery for implantable biosensors. <b>2008</b> , 2, 1016-29	29
425	Review of stent coating strategies: clinical insights. <b>2008</b> , 24, 1127-1143	30
424	Drug-eluting stents in preclinical studies: updated consensus recommendations for preclinical evaluation. <b>2008</b> , 1, 143-53	172

423	Local delivery of gene vectors from bare-metal stents by use of a biodegradable synthetic complex inhibits in-stent restenosis in rat carotid arteries. <i>Circulation</i> , <b>2008</b> , 117, 2096-103	16.7	60
422	Drug release kinetics from stent device-based delivery systems. <b>2008</b> , 51, 118-25		27
421	Postresuscitation myocardial diastolic dysfunction following prolonged ventricular fibrillation and cardiopulmonary resuscitation. <b>2008</b> , 36, 188-92		26
420	Attainment of local drug delivery with paclitaxel-eluting balloon in porcine coronary arteries. <i>Coronary Artery Disease</i> , <b>2008</b> , 19, 243-7	1.4	54
419	Gene therapy for coronary and peripheral artery disease. <b>2008</b> , 18, 903-927		0
418	Decellularized aorta of fetal pigs as a potential scaffold for small diameter tissue engineered vascular graft. <b>2008</b> , 121, 1398-1406		22
417	Next generation drug-eluting stents: focus on bioabsorbable platforms and polymers. <b>2009</b> , 2, 47-55		3
416	Long-term effects of novel biodegradable, polymer-coated, sirolimus-eluting stents on neointimal formation in a porcine coronary model. <b>2009</b> , 50, 811-22		14
415	Xience V everolimus-eluting coronary stent. <b>2009</b> , 6, 219-29		28
414	In vivo remodeling and structural characterization of fibrin-based tissue-engineered heart valves in the adult sheep model. <i>Tissue Engineering - Part A</i> , <b>2009</b> , 15, 2965-76	3.9	129
413	Bioabsorbable material-containing phosphorylcholine group-rich surfaces for temporary scaffolding of the vessel wall. <b>2009</b> , 15, 125-33		12
412	Paclitaxel-eluting balloon: from bench to bed. <b>2009</b> , 73, 643-52		52
411	Short-, mid-, and long-term effects of a polymer-free tacrolimus-eluting stent in a porcine coronary model. <b>2009</b> , 88, 872-9		7
410	Evaluation of drug-eluting stents coating durability--clinical and regulatory implications. <b>2009</b> , 91, 441-51		42
409	Absorbable polymer stent technologies for vascular regeneration. <b>2009</b> , 85, 744-751		40
408	Formulation of nanoparticle-eluting stents by a cationic electrodeposition coating technology: efficient nano-drug delivery via bioabsorbable polymeric nanoparticle-eluting stents in porcine coronary arteries. <b>2009</b> , 2, 277-83		100
407	Use of a novel anti-proliferative compound coated on a biopolymer to mitigate platelet-derived growth factor-induced proliferation in human aortic smooth muscle cells: comparison with sirolimus. <b>2009</b> , 26, 721-32		1
406	Drug-eluting stent coatings. <b>2009</b> , 1, 451-62		45

405	Passive and active polymer coatings for intracoronary stents: novel devices to promote arterial healing. <b>2009</b> , 22, 37-48	27
404	DES Design: Theoretical Advantages and Disadvantages of Stent Strut Materials, Design, Thickness, and Surface Characteristics. <b>2009</b> , 22, S3-S17	11
403	XIENCE V <sup>®</sup> Everolimus-Eluting Coronary Stent System: A Preclinical Assessment. <b>2009</b> , 22, S28-S40	29
402	Safety and efficacy of biodegradable polymer-coated sirolimus-eluting stents in "real-world" practice: 18-month clinical and 9-month angiographic outcomes. <b>2009</b> , 2, 303-9	60
401	Mechanical properties, drug eluting characteristics and in vivo performance of a genipin-crosslinked chitosan polymeric stent. <b>2009</b> , 30, 5560-71	50
400	Improving hydrophilicity, mechanical properties and biocompatibility of poly[(R)-3-hydroxybutyrate-co-(R)-3-hydroxyvalerate] through blending with poly[(R)-3-hydroxybutyrate]-alt-poly(ethylene oxide). <b>2009</b> , 5, 2002-12	49
399	Drug-eluting bioabsorbable stents - an in vitro study. <b>2009</b> , 5, 2894-900	28
398	Acrylic copolymers as candidates for drug-eluting coating of vascular stents. <b>2009</b> , 24, 353-83	5
397	Effect of blood flow on drug release from DES: an experimental study. <b>2009</b> , 131, 415-7	4
396	A rabbit model for efficacy evaluation of endovascular coil materials. <b>2009</b> , 72, 620-7; discussion 627	3
395	Electropolymerized tercopolymer based on N-pyrrole derivatives as a primer coating for improving the performance of a drug-eluting stent. <b>2009</b> , 1, 758-67	25
394	Tissue-engineered small-caliber vascular graft based on a novel biodegradable composite fibrin-poly lactide scaffold. <i>Tissue Engineering - Part A</i> , <b>2009</b> , 15, 1909-18	3-9 90
393	Advances in stent drug delivery: the future is in bioabsorbable stents. <b>2009</b> , 6, 113-26	56
392	A new wave in treatment of vascular occlusive disease: biodegradable stents--clinical experience and scientific principles. <b>2009</b> , 20, 315-24; quiz 325	36
391	Synthesis of microbial elastomers based on soybean oily acids. Biocompatibility studies. <b>2009</b> , 4, 035011	29
390	Biocompatibility of cardiovascular devices. <b>2010</b> , 54-85	1
389	Increased restenosis rates 12 months after coronary implantation of the sirolimus-eluting YUKON-choice stent compared to the paclitaxel-eluting TAXUS Stent. <b>2010</b> , 33, E33-8	1
388	Efficacy and safety of drug-eluting stent implantation for the treatment of in-stent restenosis occurring within bare-metal stent and drug-eluting stent. <b>2010</b> , 11, 553-60	6



387	Intravascular tissue reactions induced by various types of bioabsorbable polymeric materials: correlation between the degradation profiles and corresponding tissue reactions. <b>2010</b> , 52, 1017-24	11
386	Influence of unsaturated carbonic acids on hemocompatibility and cytotoxicity of poly-vinylacetate based co-polymers. <b>2010</b> , 21, 1693-702	5
385	Chitosan film containing poly(D,L-lactic-co-glycolic acid) nanoparticles: a platform for localized dual-drug release. <i>Pharmaceutical Research</i> , <b>2010</b> , 27, 1738-45	4-5 23
384	In vivo and in vitro characterization of poly(styrene-b-isobutylene-b-styrene) copolymer stent coatings for biostability, vascular compatibility and mechanical integrity. <b>2010</b> , 92, 773-82	37
383	Chronic inflammatory responses to microgel-based implant coatings. <b>2010</b> , 94, 252-8	35
382	Design of Multiresponsive Hydrogel Particles and Assemblies. <b>2010</b> , 20, 1697-1712	156
381	Laser Raman spectroscopic investigations of biodegradable vehicle of active agents eluting LVM 316 stainless steel cardiovascular stents for in vivo degradation characteristics. <b>2010</b> , 41, 363-369	2
380	Surface Modification of Nickel/Titanium Alloy and Titanium Surfaces via a Polyelectrolyte Multilayer/Calcium Phosphate Hybrid Coating. <b>2010</b> , 295, 535-543	24
379	PLGA/PVA hydrogel composites for long-term inflammation control following s.c. implantation. <b>2010</b> , 384, 78-86	75
378	In vitro characterization of polycaprolactone matrices generated in aqueous media. <b>2010</b> , 6, 1061-8	32
377	Fibrin-poly lactide-based tissue-engineered vascular graft in the arterial circulation. <b>2010</b> , 31, 4731-9	110
376	The biocompatibility of rapidly degrading polymeric stents in porcine carotid arteries. <b>2010</b> , 31, 7847-55	59
375	Scaffold Sheet Design Strategy for Soft Tissue Engineering. <b>2010</b> , 3, 1375-1389	35
374	Future outlook for drug eluting stents. <b>2010</b> , 117-153	1
373	Drug-eluting balloon: new tool in the box. <b>2010</b> , 7, 381-8	12
372	A Novel Biocompatible Poly (3-hydroxy-co-4-hydroxybutyrate) Blend as a Potential Biomaterial for Tissue Engineering. <b>2010</b> , 25, 419-436	12
371	Effect of Micro Pits Topography on the Platelets Adhesion on 316L Stainless Steel Surface. <b>2010</b> , 156-157, 422-425	0
370	Degradable metallic biomaterials for cardiovascular applications. <b>2010</b> , 379-404	6

369	Preclinical models of restenosis and their application in the evaluation of drug-eluting stent systems. <b>2010</b> , 47, 58-76	39
368	Unravelling the endovascular microenvironment by optical coherence tomography. <b>2010</b> , 31, 139-42	10
367	Drug-eluting stents: the next generation. <b>2010</b> , 2, 341-350	5
366	Benefits of and safety concerns associated with drug-eluting coronary stents. <b>2010</b> , 8, 449-70	20
365	Coronary stents: looking forward. <b>2010</b> , 56, S43-78	239
364	Coronary stents: current status. <b>2010</b> , 56, S1-42	371
363	The evolving role of inflammatory biomarkers in risk assessment after stent implantation. <b>2010</b> , 56, 1783-93	79
362	Stent thrombosis. <b>2010</b> , 56, 1357-65	312
361	Incidence and natural history of coronary artery aneurysm developing after drug-eluting stent implantation. <b>2010</b> , 160, 987-94	29
360	In vitro and in vivo characterization of novel biodegradable polymers for application as drug-eluting stent coatings. <b>2010</b> , 21, 529-52	24
359	New drug-eluting stent concepts. <b>2010</b> , 7, 194-203	96
358	Nitrogen-doped TiO <sub>2</sub> films as drug-binding matrices for the preparation of drug-eluting stents. <b>2011</b> , 21, 8169	13
357	New generation of medical implants: Metallic biodegradable coronary stent. <b>2011</b> ,	3
356	Interaction between a high purity magnesium surface and PCL and PLA coatings during dynamic degradation. <b>2011</b> , 6, 025005	110
355	Stent thrombosis did biodegradable polymers fail or are we too impatient?. <b>2011</b> , 58, 885-6; author reply 886-7	2
354	2-year clinical follow-up from the randomized comparison of biolimus-eluting stents with biodegradable polymer and sirolimus-eluting stents with durable polymer in routine clinical practice. <b>2011</b> , 4, 887-95	29
353	Assessing the temporal course of neointimal hyperplasia formation after different generations of drug-eluting stents. <b>2011</b> , 4, 1067-74	22
352	Current and future drug-eluting coronary stent technology. <b>2011</b> , 9, 485-503	19

351	Novel Coating Technologies of Drug Eluting Stents. <b>2011</b> , 87-125	3
350	Polymer-free paclitaxel-coated Zilver PTX Stents--evaluation of pharmacokinetics and comparative safety in porcine arteries. <b>2011</b> , 22, 603-10	53
349	Long-term tissue coverage of a biodegradable polylactide polymer-coated biolimus-eluting stent: comparative sequential assessment with optical coherence tomography until complete resorption of the polymer. <b>2011</b> , 162, 922-31	40
348	[Instent restenosis related to vessel injury score degree. Are current experimental models valid for drug-eluting stents analysis?]. <b>2011</b> , 64, 745-51	11
347	Local drug delivery for treatment of coronary and peripheral artery disease. <b>2011</b> , 29, e54-66	13
346	Instent Restenosis Related to Vessel Injury Score Degree. Are Current Experimental Models Valid for Drug-Eluting Stents Analysis?. <b>2011</b> , 64, 745-751	1
345	The emerging role of allergic inflammation in adverse reactions after coronary stent implantation. <b>2011</b> , 217, 70-1	5
344	Imatinib mesylate-incorporated nanoparticle-eluting stent attenuates in-stent neointimal formation in porcine coronary arteries. <b>2011</b> , 18, 1043-53	45
343	Induction of nicotinamide-adenine dinucleotide phosphate oxidase and apoptosis by biodegradable polymers in macrophages: implications for stents. <b>2011</b> , 57, 712-20	10
342	Bioresorbable scaffold technologies. <b>2011</b> , 75, 509-20	93
341	Drug-eluting stent: importance of clinico-pathological correlations. <b>2011</b> , 75, 1548-58	18
340	Outcomes following coronary stenting and a role for eosinophils: evidence from eosinophil cationic protein. <b>2011</b> , 3, 421-423	
339	Drug-eluting stents and balloons in peripheral arterial disease: evidence so far. <b>2011</b> , 65, 664-8	15
338	Recent developments in drug-eluting stents. <b>2011</b> , 89, 545-53	13
337	Biomaterials advances in patches for congenital heart defect repair. <b>2011</b> , 4, 646-54	52
336	In vitro and in vivo degradation of poly(D, L-lactide-co-glycolide)/amorphous calcium phosphate copolymer coated on metal stents. <b>2011</b> , 96, 632-8	22
335	Layer-by-layer assembly of chitosan and platelet monoclonal antibody to improve biocompatibility and release character of PLLA coated stent. <b>2011</b> , 97, 423-32	26
334	A novel polymer-free paclitaxel-eluting stent with a nanoporous surface for rapid endothelialization and inhibition of intimal hyperplasia: Comparison with a polymer-based sirolimus-eluting stent and bare metal stent in a porcine model. <b>2011</b> , 98, 629-37	9

333	Inorganic coatings for cardiovascular stents: In vitro and in vivo studies. <b>2011</b> , 96, 333-41		13
332	Comparison of pharmacokinetics of the limus-eluting stents in Japanese patients. <b>2011</b> , 78, 1078-85		9
331	How can we miss you, if you will never leave? Biodegradable stents. <b>2011</b> , 78, 167-8		
330	Biomaterial guides for lymphatic endothelial cell alignment and migration. <b>2011</b> , 7, 1104-13		20
329	Stability of Phosphonic Self Assembled Monolayers (SAMs) on Cobalt Chromium (Co-Cr) Alloy under Oxidative conditions. <b>2011</b> , 257, 5605-5612		25
328	An acetylated polysaccharide-PTFE membrane-covered stent for the delivery of gemcitabine for treatment of gastrointestinal cancer and related stenosis. <b>2011</b> , 32, 3603-10		58
327	Tissue response to poly(L-lactic acid)-based blend with phospholipid polymer for biodegradable cardiovascular stents. <b>2011</b> , 32, 2241-7		36
326	Spatiotemporal effects of a controlled-release anti-inflammatory drug on the cellular dynamics of host response. <b>2011</b> , 32, 4464-70		31
325	Use of remote film loading methodology to entrap sirolimus into liposomes: preparation, characterization and in vivo efficacy for treatment of restenosis. <b>2011</b> , 414, 16-27		35
324	Characterization of a PLGA sandwiched cell/fibrin tubular construct and induction of the adipose derived stem cells into smooth muscle cells. <b>2011</b> , 31, 801-808		12
323	Forming In-Situ Micro-Cavities on 316L Stainless Steel Surface by Aluminum Electrodeposition and Anodization Technology. <b>2011</b> , 239-242, 3354-3357		
322	Enhanced efficacy of sirolimus-eluting bioabsorbable magnesium alloy stents in the prevention of restenosis. <i>Journal of Endovascular Therapy</i> , <b>2011</b> , 18, 407-15	2.5	32
321	Nitinol stents with polymer-free paclitaxel coating for lesions in the superficial femoral and popliteal arteries above the knee: twelve-month safety and effectiveness results from the Zilver PTX single-arm clinical study. <i>Journal of Endovascular Therapy</i> , <b>2011</b> , 18, 613-23	2.5	133
320	Nanosecond Laser Induced Periodic Surface Structures on Drug Elution Profiles in Stents. <b>2012</b> , 6,		0
319	Tissue-engineered devices in cardiovascular surgery. <b>2012</b> , 49, 44-52		16
318	Biodegradable polymer and permanent polymer drug-eluting stents: at the crossroads of evidence and expectation. <b>2012</b> , 4, 147-150		
317	Synthetic Polymers: Polyesters, Polyethers, Polysulfones, and Other Polymers. <b>2012</b> , 965-998		0
316	Long-term Clinical and Angiographic Follow-up of the New Non-Polymeric Paclitaxel-Eluting Stent for the Treatment of De Novo Coronary Lesions: Outcomes of the PAX-B Study. <b>2012</b> , 20, 146-154		2

315	Biolimus-eluting stent with biodegradable polymer: one step forward in the fight against stent thrombosis vulnerability?. <b>2012</b> , 4, 11-25	1
314	Endovascular Stents. <b>2012</b> , 89-116	1
313	Bacterial Poly(Ehydroxybutyrate): Hydrophilized and Colored. <b>2012</b> , 157-169	
312	Surface chemical and physical modification in stent technology for the treatment of coronary artery disease. <b>2012</b> , 100, 1989-2014	47
311	Reducing In-Stent Restenosis Through Novel Stent Flow Field Augmentation. <b>2012</b> , 3, 353-373	24
310	Investigation of Different Drug Deposition Techniques on Drug Releasing Properties of Cardiovascular Drug Coated Balloons. <b>2012</b> , 51, 10800-10823	8
309	Biocompatible and bioactive surface modifications for prolonged in vivo efficacy. <b>2012</b> , 112, 1615-32	195
308	Sustained release of heparin on enlarged-pore and functionalized MCM-41. <b>2012</b> , 4, 4113-22	36
307	Histological confirmation of hypersensitivity as a contributor to very-late coronary stent thrombosis. <b>2012</b> , 157, e29-30	7
306	Host Response to Biomaterials. <b>2012</b> , 143-159	4
305	Optimized duration of clopidogrel therapy following treatment with the Endeavor zotarolimus-eluting stent in real-world clinical practice (OPTIMIZE) trial: rationale and design of a large-scale, randomized, multicenter study. <b>2012</b> , 164, 810-6.e3	16
304	A first-in-man study of sirolimus-eluting, biodegradable polymer coated cobalt chromium stent in real life patients. <b>2012</b> , 64, 547-52	11
303	Nanofibrous poly(3-hydroxybutyrate-co-3-hydroxyvalerate)/chitosan scaffolds for skin regeneration. <b>2012</b> , 51, 343-50	69
302	A multicenter randomized trial comparing amphilius- with paclitaxel-eluting stents in de novo native coronary artery lesions. <b>2012</b> , 59, 1371-6	85
301	Porous chitosan scaffold cross-linked by chemical and natural procedure applied to investigate cell regeneration. <b>2012</b> , 262, 218-221	20
300	Prevention of coronary in-stent restenosis and vein graft failure: does vascular gene therapy have a role?. <b>2012</b> , 136, 23-34	22
299	Restenosis after PCI. Part 2: prevention and therapy. <b>2011</b> , 9, 79-90	61
298	Site Specific Controlled Release for Cardiovascular Disease: Translational Directions. <b>2012</b> , 445-492	1

297	Biodegradable Metals: State of the Art. <b>2012</b> , 13-22	16
296	Below-the-knee drug-eluting stents and drug-coated balloons. <b>2012</b> , 9, 85-94	24
295	Polyurethane-based microfluidic devices for blood contacting applications. <b>2012</b> , 12, 960-70	43
294	Stent thrombosis: incidence, predictors and new technologies. <b>2012</b> , 2012, 956962	44
293	Nanotechnology in interventional cardiology. <b>2012</b> , 4, 82-95	14
292	Histological and molecular evaluation of iron as degradable medical implant material in a murine animal model. <b>2012</b> , 100, 2881-9	49
291	Characterization and degradation of elastomeric four-armed star copolymers based on caprolactone and L-lactide. <b>2012</b> , 100, 3436-45	15
290	Long-term effects on vascular healing of bare metal stents delivered via paclitaxel-coated balloons in the porcine model of restenosis. <b>2012</b> , 80, 603-10	16
289	Gemcitabine-releasing polymeric films for covered self-expandable metallic stent in treatment of gastrointestinal cancer. <b>2012</b> , 427, 276-83	34
288	Novel nanocomposite stent coating releasing resveratrol and quercetin reduces neointimal hyperplasia and promotes re-endothelialization. <b>2012</b> , 159, 27-33	37
287	Process of prototyping coronary stents from biodegradable Fe-Mn alloys. <b>2013</b> , 9, 8585-92	56
286	Progress in treatment by percutaneous coronary intervention: the stent of the future. <b>2013</b> , 66, 483-96	13
285	Sirolimus-loaded stealth colloidal systems attenuate neointimal hyperplasia after balloon injury: a comparison of phospholipid micelles and liposomes. <b>2013</b> , 455, 320-30	28
284	Endoprótesis coronarias bioabsorbibles. <b>2013</b> , 13, 29-39	
283	Fabrication of a novel polymer-free nanostructured drug-eluting coating for cardiovascular stents. <b>2013</b> , 5, 10337-45	52
282	Experience with BioMatrix BES and other DES in all-comers setting: a retrospective overview. <b>2013</b> , 65, 678-82	6
281	Drug eluting balloon versus drug eluting stent in percutaneous coronary interventions: insights from a meta-analysis of 1462 patients. <b>2013</b> , 168, 4608-16	16
280	In vitro stability study of organophosphonic self assembled monolayers (SAMs) on cobalt chromium (Co-Cr) alloy. <b>2013</b> , 33, 2050-8	19

279	A multilayered scaffold of a chitosan and gelatin hydrogel supported by a PCL core for cardiac tissue engineering. <b>2013</b> , 9, 5630-42	147
278	FT-IR characterization and hydrolysis of PLA-PEG-PLA based copolyester hydrogels with short PLA segments and a cytocompatibility study. <b>2013</b> , 51, 5163-5176	32
277	Biodegradable poly(l-lactide) composites by oligolactide-grafted magnesium hydroxide for mechanical reinforcement and reduced inflammation. <b>2013</b> , 1, 2764-2772	48
276	Coordination chemistry for antibacterial materials: a monolayer of a Cu(2+) 2,2'Cbipyridine complex grafted on a glass surface. <b>2013</b> , 42, 4552-60	17
275	Tailoring the properties of electrospun PHBV mats: Co-solution blending and selective removal of PEO. <b>2013</b> , 49, 3210-3222	18
274	One-year clinical outcomes of BioMatrix[Biolimus A9]eluting stent: the e-BioMatrix multicenter post marketing surveillance registry in India. <b>2013</b> , 65, 593-9	10
273	Avances en el tratamiento mediante intervenci3n coronaria percut3nea: el stent del futuro. <b>2013</b> , 66, 483-496	47
272	Adenoviral vector tethering to metal surfaces via hydrolyzable cross-linkers for the modulation of vector release and transduction. <b>2013</b> , 34, 6938-48	10
271	Elastomeric biomaterials for tissue engineering. <b>2013</b> , 38, 584-671	351
270	Significantly Accelerated Spherulitic Growth Rates for Semicrystalline Polymers through the Layer-by-Layer Film Method. <b>2013</b> , 117, 5882-5893	26
269	Inception to actualization: next generation coronary stent coatings incorporating nanotechnology. <b>2013</b> , 164, 151-70	49
268	Drug-eluting coronary-artery stents. <b>2013</b> , 368, 254-65	499
267	Development and characterization of a coronary polylactic acid stent prototype generated by selective laser melting. <b>2013</b> , 24, 241-55	33
266	Large-ring lactones from plant oils. <b>2013</b> , 15, 2361	26
265	Dual drug-eluting stents coated with multilayers of hydrophobic heparin and sirolimus. <b>2013</b> , 5, 12944-53	34
264	Photofunctional Co-Cr Alloy Generating Reactive Oxygen Species for Photodynamic Applications. <b>2013</b> , 2013, 1-8	2
263	Experience with biodegradable polymer coated sirolimus-eluting coronary stent system in "real-life" percutaneous coronary intervention: 24-month data from the manipal-s registry. <b>2013</b> , 7, 1959-63	3
262	Multi-Objective Design of a Biodegradable Coronary Artery Stent. <b>2013</b> , 1-28	2

261	Materials and methods for the microfabrication of microfluidic biomedical devices. <b>2013</b> , 3-62	7
260	Dexamethasone-eluting vascular stents. <b>2013</b> , 112, 296-301	10
259	Hemocompatibility of polymeric nanostructured surfaces. <b>2013</b> , 24, 1529-48	42
258	Poly (D,L) lactic acid blending with vitamin E increases polymer hemocompatibility: An hydrophilic effect. <b>2013</b> , 129, 1527-1533	6
257	One-year outcomes of consecutive patients treated by Endeavor zotarolimus and Resolute zotarolimus stents: the impact of polymer coating in drug-eluting stent technology. <b>2013</b> , 81, 268-73	7
256	Bioresorbable scaffolds in the treatment of coronary artery disease. <b>2013</b> , 6, 37-48	11
255	Pitavastatin-incorporated nanoparticle-eluting stents attenuate in-stent stenosis without delayed endothelial healing effects in a porcine coronary artery model. <b>2013</b> , 20, 32-45	47
254	Endovascular Gene Delivery from a Stent Platform: Gene- Eluting Stents. <b>2013</b> , 1,	4
253	Bioabsorbable stent quo vadis: a case for nano-theranostics. <b>2014</b> , 4, 514-33	10
252	Advances in stent technologies and their effect on clinical efficacy and safety. <b>2014</b> , 7, 165-78	5
251	Performance of the Titanium-Nitride-Oxide Coated Stent in Patients with Multivessel Coronary Artery Disease. <b>2014</b> , 22, 143-148	3
250	Effect of magnesium hydroxide nanoparticles with rod and plate shape on mechanical and biological properties of poly(L-lactide) composites. <b>2014</b> , 22, 1032-1041	9
249	Association between inflammatory biomarkers and in-stent restenosis tissue features: an Optical Coherence Tomography Study. <b>2014</b> , 15, 917-25	12
248	Biomaterials in cardiovascular research: applications and clinical implications. <b>2014</b> , 2014, 459465	76
247	Terapia de restauraci3n vascular con plataformas biorreabsorbibles. La cuarta revoluci3n. <b>2014</b> , 21, 231-240	1
246	First report of a novel polymer-free dual-drug eluting stent in de novo coronary artery disease: results of the first in human BICARE trial. <b>2014</b> , 83, 405-11	13
245	Biodegradable versus durable polymer drug eluting stents in coronary artery disease: insights from a meta-analysis of 5,834 patients. <b>2014</b> , 21, 411-24	20
244	Bioresorbable scaffolds for percutaneous coronary interventions. <b>2014</b> , 2014, 409-27	11



243	Polymeric stent materials dysregulate macrophage and endothelial cell functions: implications for coronary artery stent. <b>2014</b> , 174, 688-95	7
242	Safety and efficacy of degradable vs. permanent polymer drug-eluting stents: a meta-analysis of 18,395 patients from randomized trials. <b>2014</b> , 173, 100-9	7
241	Clinical outcomes with bioabsorbable polymer- versus durable polymer-based drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. <b>2014</b> , 63, 299-307	217
240	Permanent polymer of drug eluting stents increases eosinophil cationic protein levels following percutaneous coronary intervention independently of C-reactive protein. <b>2014</b> , 237, 816-20	2
239	Development and assessment of a biodegradable solvent cast polyester fabric small-diameter vascular graft. <b>2014</b> , 102, 1972-1981	18
238	Influence of Thermal Annealing on the Mechanical Properties of PLLA Coiled Stents. <b>2014</b> , 5, 270-280	15
237	Polymer-free drug-eluting stent in unselected patient population: a single center experience. <b>2014</b> , 15, 350-3	6
236	Nanostructured biomaterials from electrospun demineralized bone matrix: a survey of processing and crosslinking strategies. <b>2014</b> , 6, 9328-37	26
235	Choosing the right coronary stent in the modern era. <b>2014</b> , 16, 469	1
234	Deconstructing stent polymers. <b>2014</b> , 63, 308-9	3
233	Numerical modelling of the physical factors that affect mass transport in the vasculature at early time periods. <b>2014</b> , 36, 308-17	3
232	Evaluation of the biodegradable peripheral Igaki-Tamai stent in the treatment of de novo lesions in the superficial femoral artery: the GAIA study. <b>2014</b> , 7, 305-12	43
231	Coronary drug-eluting stents: from design optimization to newer strategies. <b>2014</b> , 102, 1625-40	42
230	Favorable vessel healing after nobori biolimus A9-eluting stent implantation-6- and 12-month follow-up by optical coherence tomography. <b>2014</b> , 78, 1882-90	13
229	First-in-Man Study of the Low-Dose Paclitaxel Using the COBRA-P Drug-Eluting Coronary Stent System With a Novel Biodegradable Coating in De Novo Coronary Lesions. <b>2014</b> , 84, 1101-1109	
228	Clinical, angiographic, and intravascular ultrasound results of the VestSaync II trial. <b>2014</b> , 84, 1073-9	10
227	Performance of the Titanium-Nitride-Oxide Coated Stent in Patients with Multivessel Coronary Artery Disease. <b>2014</b> , 22, 143-148	
226	Polymer-free versus permanent polymer drug eluting stents in coronary artery disease: A meta-analysis of 10 RCTs with 6575 patients. <b>2015</b> , 1, 221-230	9

225	Human recombinant activated protein C-coated stent for the prevention of restenosis in porcine coronary arteries. <b>2015</b> , 26, 241	4
224	Recent advances in biodegradable metals for medical sutures: a critical review. <i>Advanced Healthcare Materials</i> , <b>2015</b> , 4, 1915-36	10.1 140
223	Rapid prototyped sutureless anastomosis device from self-curing silk bio-ink. <b>2015</b> , 103, 1333-43	12
222	Biodegradable Materials for Bone Repair and Tissue Engineering Applications. <b>2015</b> , 8, 5744-5794	373
221	Polymers for Cardiovascular Stent Coatings. <b>2015</b> , 2015, 1-11	39
220	Polymer-Free Drug-Eluting Stents: An Overview of Coating Strategies and Comparison with Polymer-Coated Drug-Eluting Stents. <b>2015</b> , 26, 1277-88	51
219	Some design considerations for polymer-free drug-eluting stents: a mathematical approach. <b>2015</b> , 18, 213-25	33
218	Progress in interventional cardiology: challenges for the future. <b>2015</b> , 113, 464-72	12
217	Development of Magnesium Alloy Scaffolds to Support Biological Myocardial Grafts: A Finite Element Investigation. <b>2015</b> , 81-100	
216	Polymers in Cardiology. <b>2015</b> , 433-480	1
215	Vascular response to bioresorbable polymer sirolimus-eluting stent vs. permanent polymer everolimus-eluting stent at 9-month follow-up: an optical coherence tomography sub-study from the CENTURY II trial. <b>2016</b> , 17, 34-40	19
214	Controlling drug delivery from coronary stents: are we aiming for the right targets?. <b>2015</b> , 6, 705-20	3
213	Muraglitazar-eluting bioabsorbable vascular stent inhibits neointimal hyperplasia in porcine iliac arteries. <b>2015</b> , 26, 124-30	5
212	Editorial: Is there any difference between coronary stent thrombosis and peripheral arterial stent thrombosis?. <b>2015</b> , 11, 42-43	
211	Local delivery of paclitaxel in the treatment of peripheral arterial disease. <b>2015</b> , 45, 333-45	37
210	Biocompatibility of MgF <sub>2</sub> -coated MgNd <sub>2</sub> specimens in contact with mucosa of the nasal sinus - a long term study. <b>2015</b> , 18, 249-61	15
209	Reliable femoral chronic total occlusion model using a thin biodegradable polymer coated copper stent in a porcine model. <b>2015</b> , 26, 172	2
208	Blood compatibility of a ferulic acid (FA)-eluting PHBHHx system for biodegradable magnesium stent application. <b>2015</b> , 52, 37-45	15

207	Biocompatibility of shape-memory polymers for biomedical applications. <b>2015</b> , 77-95	
206	In vitro evaluation of paclitaxel coatings for delivery via drug-coated balloons. <b>2015</b> , 96, 322-8	22
205	Applications of synthetic polymers in clinical medicine. <b>2015</b> , 1, 161-176	397
204	A hypothesis-driven parametric study of effects of polymeric scaffold properties on tissue engineered neovessel formation. <b>2015</b> , 11, 283-94	45
203	Spray- and laser-assisted biomaterial processing for fast and efficient autologous cell-plus-matrix tissue engineering. <b>2015</b> , 9, E177-90	11
202	Business Perspective. <b>2016</b> , 405-419	
201	Improved Biocompatibility of Novel Biodegradable Scaffold Composed of Poly-L-lactic Acid and Amorphous Calcium Phosphate Nanoparticles in Porcine Coronary Artery. <b>2016</b> , 2016, 1-8	10
200	The Development of Coronary Artery Stents: From Bare-Metal to Bio-Resorbable Types. <b>2016</b> , 6, 168	24
199	Polymeric Biodegradable Stent Insertion in the Esophagus. <b>2016</b> , 8,	8
198	Long Term Outcome after Application of the Angio-Seal Vascular Closure Device in Minipigs. <b>2016</b> , 11, e0163878	5
197	Very late stent thrombosis with second generation drug eluting stents compared to bare metal stents: Network meta-analysis of randomized primary percutaneous coronary intervention trials. <b>2016</b> , 88, 38-48	32
196	Six-month outcomes of the XINSORB bioresorbable sirolimus-eluting scaffold in treating single de novo lesions in human coronary artery. <b>2016</b> , 87 Suppl 1, 630-7	15
195	Development of a novel dual PLGA and alginate coated drug-eluting stent for enhanced blood compatibility. <b>2016</b> , 24, 931-939	6
194	Nanotechnology in Coronary Artery Stent Coating. <b>2016</b> , 437-463	1
193	Bench and initial preclinical results of a novel 8 mm diameter double opposed helical biodegradable stent. <b>2016</b> , 88, 902-911	8
192	Biomaterials for Biomedical Applications. <b>2016</b> , 1-20	4
191	Treatment of the femoropopliteal artery with the bioresorbable REMEDY stent. <b>2016</b> , 64, 1311-1319	13
190	Long Coronary Lesions Treated With Thin Strut Bioresorbable Polymer Drug Eluting Stent: Experience From Multicentre Randomized CENTURY II Study. <b>2016</b> , 29, 47-56	15

189	Drug deposition in coronary arteries with overlapping drug-eluting stents. <b>2016</b> , 238, 1-9	22
188	Effect of stents coated with a combination of sirolimus and alpha-lipoic acid in a porcine coronary restenosis model. <b>2016</b> , 27, 66	9
187	Techniques in Vascular and Interventional Radiology Drug Delivery Technologies in the Superficial Femoral Artery. <b>2016</b> , 19, 145-52	2
186	Impact of the bioresorbable vascular scaffold surface area on on-treatment platelet reactivity. <b>2016</b> , 27, 446-51	3
185	A review on biodegradable materials for cardiovascular stent application. <b>2016</b> , 10, 238-259	35
184	A Nuclear Magnetic Resonance Spectroscopy as a Method for Evaluation of In Vivo Poly-L-Lactide Biodegradation Kinetics From Stent-Polymer Matrices: An Experimental Study Utilizing Porcine Model of In-Stent Restenosis. <b>2016</b> , 21, 93-9	5
183	Coating Techniques and Release Kinetics of Drug-Eluting Stents. <b>2019</b> , 10,	18
182	Drug-Eluting Stents Are the Default Strategy for Superficial Femoral Artery Intervention Now. <i>Circulation</i> , <b>2016</b> , 133, 320-9; discussion 329	16.7 3
181	Biomechanical Challenges to Polymeric Biodegradable Stents. <b>2016</b> , 44, 560-79	37
180	Magnesium from bioresorbable implants: Distribution and impact on the nano- and mineral structure of bone. <b>2016</b> , 76, 250-60	54
179	Randomized Trial of Polymer-Free Sirolimus- and Probuocol-Eluting Stents Versus Durable Polymer Zotarolimus-Eluting Stents: 5-Year Results of the ISAR-TEST-5 Trial. <b>2016</b> , 9, 784-792	42
178	The use of polymer-based nanoparticles and nanostructured materials in treatment and diagnosis of cardiovascular diseases: Recent advances and emerging designs. <b>2016</b> , 57, 153-178	38
177	Polymer-Free Biolimus A9-Coated Stents in the Treatment of De Novo Coronary Lesions: 4- and 12-Month Angiographic Follow-Up and Final 5-Year Clinical Outcomes of the Prospective, Multicenter BioFreedom FIM Clinical Trial. <b>2016</b> , 9, 51-64	55
176	Beneficial Effects of a Novel Bioabsorbable Polymer Coating on Enhanced Coronary Vasoconstricting Responses After Drug-Eluting Stent Implantation in Pigs in Vivo. <b>2016</b> , 9, 281-291	13
175	Nanotechnology in diagnosis and treatment of coronary artery disease. <b>2016</b> , 11, 513-30	44
174	Time-related changes in neointimal tissue coverage of a novel Sirolimus eluting stent: Serial observations with optical coherence tomography. <b>2016</b> , 17, 38-43	15
173	Optical coherence tomography evaluation of intermediate-term healing of different stent types: systemic review and meta-analysis. <b>2017</b> , 18, 159-166	48
172	Bioresorbable Scaffolds for Coronary Artery Disease. <b>2017</b> , 19, 5	4

171	Paclitaxel-Coated Balloon for Femoropopliteal Artery Disease. <b>2017</b> , 19, 10		12
170	Meta-Analysis of Randomized Clinical Trials Comparing Biodegradable Polymer Drug-Eluting Stent to Second-Generation Durable Polymer Drug-Eluting Stents. <b>2017</b> , 10, 462-473		102
169	Polymer-Free Drug-Coated Coronary Stents in Patients with Stable Coronary Artery Disease at High Bleeding Risk. <b>2017</b> , 19, 12		3
168	A head to head comparison of XINSORB bioresorbable sirolimus-eluting scaffold versus metallic sirolimus-eluting stent: 180 days follow-up in a porcine model. <b>2017</b> , 33, 1473-1481		6
167	Comparison Study on Four Biodegradable Polymer Coatings for Controlling Magnesium Degradation and Human Endothelial Cell Adhesion and Spreading. <b>2017</b> , 3, 936-950		40
166	Development of Zn-Based Degradable Metallic Biomaterials. <b>2017</b> , 161-188		
165	Can the Vanishing Stent Reappear?: Fix the Technique, or Fix the Device?. <b>2017</b> , 70, 2875-2877		5
164	Ultrathin, bioresorbable polymer sirolimus-eluting stents versus thin, durable polymer everolimus-eluting stents in patients undergoing coronary revascularisation (BIOFLOW V): a randomised trial. <b>2017</b> , 390, 1843-1852		159
163	Stent-based delivery of adeno-associated viral vectors with sustained vascular transduction and iNOS-mediated inhibition of in-stent restenosis. <b>2017</b> , 24, 717-726		16
162	Polymer-free Biolimus A9-coated stents in the treatment of de novo coronary lesions with short DAPT: 9-month angiographic and clinical follow-up of the prospective, multicenter BioFreedom USA clinical trial. <b>2017</b> , 18, 475-481		6
161	Five-year follow-up of polymer-free sirolimus- and probucol-eluting stents versus new generation zotarolimus-eluting stents in patients presenting with st-elevation myocardial infarction. <b>2017</b> , 89, 367-374		6
160	Coronary Artery Aneurysms: A Review of the Epidemiology, Pathophysiology, Diagnosis, and Treatment. <i>Frontiers in Cardiovascular Medicine</i> , <b>2017</b> , 4, 24	5-4	112
159	7.28 Drug Eluting Stents ?. <b>2017</b> , 548-590		
158	Bioresorbable scaffolds versus metallic stents in routine PCI: the plot thickens. <i>Journal of Thoracic Disease</i> , <b>2017</b> , 9, 2296-2300	2.6	2
157	Polymer-free drug-eluting stents for coronary artery disease. <b>2018</b> , 31, 330-337		17
156	Linear Micro-patterned Drug Eluting Balloon (LMDEB) for Enhanced Endovascular Drug Delivery. <b>2018</b> , 8, 3666		4
155	Hypersensitivity to Cardiovascular Implants: Stents. <b>2018</b> , 263-271		0
154	How should we assess the performance of biodegradable polymer?. <b>2018</b> , 259, 69-70		

153	Randomised comparison of vascular response to biodegradable polymer sirolimus eluting and permanent polymer everolimus eluting stents: An optical coherence tomography study. <b>2018</b> , 258, 42-49	9
152	Mapping intermediate degradation products of poly(lactic-co-glycolic acid) in vitro. <b>2018</b> , 106, 1129-1137	7
151	Long-term results of a sirolimus-eluting stent with biodegradable polymer (RAPSTROM) in de novo coronary stenoses. <b>2018</b> , 19, 429-432	0
150	Synthesis of a bio-inspired catechol/phosphorylcholine surface modifier and characterization of its surface properties. <b>2018</b> , 56, 38-49	4
149	Evaluation of chemical stability of polymers of XIENCE everolimus-eluting coronary stents in vivo by pyrolysis-gas chromatography/mass spectrometry. <b>2018</b> , 106, 1721-1729	10
148	The development of bioresorbable composite polymeric implants with high mechanical strength. <b>2018</b> , 17, 96-103	76
147	Investigation of the influence of the composition on mechanical properties poly(glycolide-DL-lactide). <b>2018</b> , 347, 012042	1
146	Investigation of the influence of the composition on mechanical properties of polylactide. <b>2018</b> , 347, 012026	4
145	Biodegradable polymer versus second-generation durable polymer drug-eluting stents in patients with coronary artery disease: A meta-analysis. <b>2018</b> , 1, e93	2
144	Polymer-free drug-eluting stents. <b>2018</b> , 57-74	
143	Cardiovascular stents: overview, evolution, and next generation. <b>2018</b> , 7, 175-205	74
142	Advances and Challenges of Biodegradable Implant Materials with a Focus on Magnesium-Alloys and Bacterial Infections. <b>2018</b> , 8, 532	36
141	Validation Model of a Novel Anti-Inflammatory Scaffold in Interleukin-10 Knockout Mouse. <b>2018</b> , 15, 381-392	4
140	Six-month evaluation of novel bioabsorbable scaffolds composed of poly-L-lactic acid and amorphous calcium phosphate nanoparticles in porcine coronary arteries. <b>2018</b> , 33, 227-233	3
139	Stents and the Endothelium. <b>2018</b> , 597-608	
138	On the importance of modeling balloon folding, pleating, and stent crimping: An FE study comparing experimental inflation tests. <b>2019</b> , 35, e3249	10
137	Study of polylactide degradation rate in a phosphate buffer solution. <b>2019</b> , 525, 012100	
136	The influence of alloying and fabrication techniques on the mechanical properties, biodegradability and biocompatibility of zinc: A comprehensive review. <b>2019</b> , 87, 1-40	158

135	Synthesis, Nanomechanical Characterization and Biocompatibility of a Chitosan-Graft-Poly( $\epsilon$ -caprolactone) Copolymer for Soft Tissue Regeneration. <b>2019</b> , 12,	9
134	Study of the effect of the introduction of heparin on the mechanical properties of polylactide. <b>2019</b> , 525, 012098	2
133	Natural and synthetic bone replacement graft materials for dental and maxillofacial applications. <b>2019</b> , 347-376	11
132	Trimethylamine -oxide-derived zwitterionic polymers: A new class of ultralow fouling bioinspired materials. <b>2019</b> , 5, eaaw9562	81
131	Persulfated flavonoids accelerated re-endothelialization and improved blood compatibility for vascular medical implants. <b>2019</b> , 181, 174-184	8
130	The Bioresorbable Vascular Scaffold Tale 'Epilogue: Overpromised, Underdelivered, Prematurely Degraded. <b>2019</b> , 12, 980-982	
129	Newer-generation Metallic Stents: Design, Performance Characteristics, and Outcomes. <b>2019</b> , 8, 95-109	1
128	Mechanical properties and degradation of drug eluted bioresorbable vascular scaffolds prepared by three-dimensional printing technology. <b>2019</b> , 30, 547-560	8
127	Poly(-3-hydroxybutyrate-co-3-hydroxyvalerate) (PHBV): Current advances in synthesis methodologies, antitumor applications and biocompatibility. <b>2019</b> , 51, 115-126	42
126	Study of the effects of the introduction of heparin on the mechanical properties of poly (glycolide-dl-lactide). <b>2019</b> , 525, 012099	
125	Synergistically enhanced osteoconductivity and anti-inflammation of PLGA/ $\beta$ -TCP/Mg(OH) composite for orthopedic applications. <b>2019</b> , 94, 65-75	21
124	Bioresorbable polymer-coated thin strut sirolimus-eluting stent vs durable polymer-coated everolimus-eluting stent in daily clinical practice: Propensity matched one-year results from interventional cardiology network registry. <b>2019</b> , 93, E362-E368	3
123	Feasibility study of use of rabbit blood to evaluate platelet activation by medical devices. <b>2020</b> , 185, 171-179	2
122	Evolution of metallic cardiovascular stent materials: A comparative study among stainless steel, magnesium and zinc. <b>2020</b> , 230, 119641	58
121	Abbreviated Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in High Bleeding Risk Patients: LEADERS-FREE and ONYX ONE. <b>2020</b> , 9, 441-449	
120	Biodegradable phosphorylcholine copolymer for cardiovascular stent coating. <b>2020</b> , 8, 5361-5368	13
119	Clinical Prognosis Associated With the Use of Overlapping Stents With Homogenous Versus Heterogeneous Pharmacological Characteristics for the Treatment of Diffuse Coronary Artery Disease. <b>2020</b> , 21, 1355-1359	
118	Zilver PTX peripheral paclitaxel-eluting stent: a technology evaluation. <b>2020</b> , 17, 1335-1343	

117	A review on synthesis and biomedical applications of polyglycolic acid. <b>2020</b> , 27, 1	31
116	Real-world reasons and outcomes for 1-month versus longer dual antiplatelet therapy strategies with a polymer-free BIOLIMUS A9-coated stent. <b>2020</b> , 96, E248-E256	1
115	One-year outcomes of patients undergoing complex percutaneous coronary intervention with three contemporary drug-eluting stents. <b>2021</b> , 97, 1341-1351	2
114	Influence of PLGA nanoparticles on the deposition of model water-soluble biocompatible polymers by dip coating. <b>2021</b> , 608, 125591	5
113	Materials and methods for microfabrication of microfluidic devices. <b>2021</b> , 1-78	2
112	A serial optical frequency-domain imaging study of early and late vascular responses to bioresorbable-polymer sirolimus-eluting stents for the treatment of acute myocardial infarction and stable coronary artery disease patients: results of the MECHANISM-ULTIMASTER study. <b>2021</b> , 1	3
111	Long-term clinical outcomes of biodegradable polymer drug eluting stents versus second-generation durable polymer drug eluting stents for ST-segment elevation myocardial infarction. <b>2021</b> , 35, 98-98	
110	Early Vascular Healing Following Bioresorbable-Polymer Sirolimus-Eluting Stent Placement Compared to That with Durable-Polymer Everolimus-Eluting Stent. <b>2021</b> , 62, 510-519	
109	Arterial Healing 10 Months After Implantation of an Ultrathin-Strut, Biodegradable-Polymer, Sirolimus-Eluting Stent - An Angioscopic Study. <b>2021</b> , 3, 316-323	0
108	Vascular Response of a Polymer-Free Paclitaxel-Coated Stent (Zilver PTX) versus a Polymer-Coated Paclitaxel-Eluting Stent (Eluvia) in Healthy Swine Femoropopliteal Arteries. <b>2021</b> , 32, 792-801.e5	4
107	The Role of Biodegradable Poly-(L-lactide)-Based Polymers in Blood Cell Activation and Platelet-Monocyte Interaction. <b>2021</b> , 22,	0
106	Thin-Strut BRS: Revival of a Failed Revolution?. <b>2021</b> , 14, 1463-1465	0
105	Aneurysmal degeneration of fluoropolymer-coated paclitaxel-eluting stent in the superficial femoral artery: a rising concern. <b>2021</b> , 4, 56	1
104	Coronary Stenting: Reflections on a 35-Year Journey. <b>2021</b> ,	0
103	The Development of Design and Manufacture Techniques for Bioresorbable Coronary Artery Stents. <b>2021</b> , 12,	1
102	Two-Year Clinical Outcomes of Biodegradable Polymer vs. Durable Polymer Drug-Eluting Stent Implantation in Patients With End-Stage Renal Disease on Dialysis. <b>2020</b> , 3, 18-25	4
101	Applications of Polyhydroxyalkanoates (PHA) in Medicine and Pharmacy. <b>2002</b> ,	30
100	Health Issues of Biopolymers: Polyhydroxybutyrate. <b>2002</b> ,	2



99	New Degradable Resins. 423-438		1
98	Theoretical Modeling of Cyclically Loaded, Biodegradable Cylinders. <b>2007</b> , 125-177		6
97	Coronary Stents. <b>2019</b> , 1-13		1
96	Cardiovascular tissue engineering. <b>2020</b> , 249-272		3
95	Bare Metal and Drug-Eluting Coronary Stents. <b>2012</b> , 171-196		3
94	Biomaterials and Stent Technology. <b>2003</b> ,		1
93	Two cases of very late stent thrombosis after implantation of a sirolimus-eluting stent presenting as AMI. <b>2007</b> , 48, 393-7		6
92	Ideal coronary stent: development, characteristics, and vessel size impact. <b>2020</b> , 74, 191-197		1
91	Benchside testing of drug-eluting stent surface and geometry. <b>2010</b> , 2, 159-175		15
90	Current requirements for polymeric biomaterials in otolaryngology. <b>2009</b> , 8, Doc11		3
89	Bioresorbable Scaffolds: The Revolution in Coronary Stenting?. <b>2016</b> , 3, 126-146		2
88	State of the art: the inception, advent and future of fully bioresorbable scaffolds. <i>EuroIntervention</i> , <b>2017</b> , 13, 734-750	3.1	20
87	Long-term clinical outcomes after bioresorbable and permanent polymer drug-eluting stent implantation: final five-year results of the CENTURY II randomised clinical trial. <i>EuroIntervention</i> , <b>2018</b> , 14, e343-e351	3.1	17
86	Dual antiplatelet therapy strategies and clinical outcomes in patients treated with polymer-free biolimus A9-coated stents. <i>EuroIntervention</i> , <b>2020</b> , 15, e1358-e1365	3.1	4
85	The importance of large animal atherosclerosis models in studying the response to polymers and drug-eluting stents. <i>EuroIntervention</i> , <b>2018</b> , 13, 1626-1628	3.1	1
84	Safety and efficacy of multiple, overlapping polymer-based paclitaxel-eluting stents. <i>EuroIntervention</i> , <b>2007</b> , 3, 213-21	3.1	11
83	Biodegradable-polymer-based, sirolimus-eluting Supralimus stent: 6-month angiographic and 30-month clinical follow-up results from the series I prospective study. <i>EuroIntervention</i> , <b>2008</b> , 4, 59-63	3.1	39
82	The neointimal response to stents eluting tacrolimus from a degradable coating depends on the balance between polymer degradation and drug release. <i>EuroIntervention</i> , <b>2008</b> , 4, 139-47	3.1	11

81	Novel fully bioabsorbable salicylate-based sirolimus-eluting stent. <i>EuroIntervention</i> , <b>2009</b> , 5 Suppl F, F58-64	3.1	46
80	A.R.T.: concept of a bioresorbable stent without drug elution. <i>EuroIntervention</i> , <b>2009</b> , 5 Suppl F, F83-7	3.1	21
79	Assimilating the current clinical data of fully bioabsorbable stents. <i>EuroIntervention</i> , <b>2009</b> , 5 Suppl F, F103-8	3.1	11
78	The bioabsorption process: tissue and cellular mechanisms and outcomes. <i>EuroIntervention</i> , <b>2009</b> , 5 Suppl F, F28-35	3.1	44
77	Coating bioabsorption and chronic bare metal scaffolding versus fully bioabsorbable stent. <i>EuroIntervention</i> , <b>2009</b> , 5 Suppl F, F36-42	3.1	8
76	Late loss in a disappearing frame of reference: is it still applicable to fully absorbable scaffolds?. <i>EuroIntervention</i> , <b>2009</b> , 5 Suppl F, F43-8	3.1	4
75	A randomised comparison of novolimus-eluting and zotarolimus-eluting coronary stents: 9-month follow-up results of the EXCELLA II study. <i>EuroIntervention</i> , <b>2010</b> , 6, 195-205	3.1	37
74	The twelve-month outcomes of a biolimus eluting stent with a biodegradable polymer compared with a sirolimus eluting stent with a durable polymer. <i>EuroIntervention</i> , <b>2010</b> , 6, 233-239	3.1	39
73	The outcome of bifurcation lesion stenting using a biolimus-eluting stent with a bio-degradable polymer compared to a sirolimus-eluting stent with a durable polymer. <i>EuroIntervention</i> , <b>2011</b> , 6, 928-35	3.1	16
72	Effect of paclitaxel elution from reservoirs with bioabsorbable polymer compared to a bare metal stent for the elective percutaneous treatment of de novo coronary stenosis: the EUROSTAR-II randomised clinical trial. <i>EuroIntervention</i> , <b>2011</b> , 7, 64-73	3.1	7
71	Clinical performance of drug-eluting stents with biodegradable polymeric coating: a meta-analysis and systematic review. <i>EuroIntervention</i> , <b>2011</b> , 7, 505-16	3.1	28
70	Paclitaxel-coated balloon in combination with bare metal stent for treatment of de novo coronary lesions: an optical coherence tomography first-in-human randomised trial, balloon first vs. stent first. <i>EuroIntervention</i> , <b>2011</b> , 7, 711-22	3.1	36
69	The three year follow-up of the randomised "all-comers" trial of a biodegradable polymer biolimus-eluting stent versus permanent polymer sirolimus-eluting stent (LEADERS). <i>EuroIntervention</i> , <b>2011</b> , 7, 789-95	3.1	34
68	Cre8[coronary stent: preclinical in vivo assessment of a new generation polymer-free DES with Amphilimus[formulation. <i>EuroIntervention</i> , <b>2012</b> , 7, 1087-94	3.1	31
67	Adjusting a polymer formulation for an optimal bioresorbable stent: a 6-month follow-up study. <i>EuroIntervention</i> , <b>2012</b> , 8, 242-9	3.1	12
66	STACCATO (Assessment of Stent sTrut Apposition and Coverage in Coronary ArTeries with Optical coherence tomography in patients with STEMI, NSTEMI and stable/unstable angina undergoing everolimus vs. biolimus A9-eluting stent implantation): a randomised controlled trial. <i>EuroIntervention</i> , <b>2016</b> , 11, e1619-26	3.1	17
65	Initial evidence for the return of coronary vasoreactivity following the absorption of bioabsorbable magnesium alloy coronary stents. <i>EuroIntervention</i> , <b>2009</b> , 4, 481-4	3.1	54
64	Angiographic and intravascular ultrasound findings following implantation of the Endeavor zotarolimus-eluting stents in patients from the real-world clinical practice. <i>EuroIntervention</i> , <b>2009</b> , 5, 355-62	3.1	7

- 63 Comparison of 9-Month Angiographic Follow-Up and Long-Term Clinical Outcomes of Biodegradable Polymer Drug-Eluting Stents and Second-Generation Durable Polymer Drug-Eluting Stents in Patients Undergoing Single Coronary Artery Stenting. **2020**, 36, 97-104 5
- 62 New Degradable Resins. **2001**, 423-438
- 61 Drug-eluting Stents. **2001**, 297-298
- 60 The Genius Coronary Stent. **2001**, 123-130
- 59 Entwicklungsmöglichkeiten. **2002**, 297-303
- 58 Coronary Artery Revascularization: Percutaneous Approach. **2002**, 820-840
- 57 Ergebnisse bei verschiedenen Stenttypen und verschiedener Lokalisation. **2002**, 277-296
- 56 ?????????????? : 2.????????????????(65????????????). *Journal of JCS Cardiologists*, **2002**, 10, 47-53 0.1
- 55 ADIPOSE STROMAL CELL THERAPY FOR CARDIOVASCULAR DISEASE. **2003**, 293-297
- 54 Requirements for Quantitative Analysis of Intimal Reaction in Arteries Treated With Intraluminal Stents. *Journal of Endovascular Therapy*, **2003**, 10, 1110-1116 2.5 1
- 53 Primary angioplasty for acute myocardial infarction. **2004**, 292-311
- 52 Methotrexate loaded BOBSC-coated coronary stents reduce neointimal hyperplasia in a porcine coronary model. **2005**, 325-336
- 51 Complications related to drug-eluting stents Jose A Silva. **2005**, 106-115
- 50 The PC-coated BiodivYsio™ stent. **2005**, 115-119
- 49 Drug-Eluting Coronary Stents. **2007**, 1031-1050
- 48 Biodegradable Stents. **2007**, 369-375
- 47 The application of controlled drug delivery principles to the development of drug-eluting stents. **2007**, 267-278
- 46 Bioabsorbable Material Containing Phosphorylcholine Group-Rich Surfaces for Temporary Scaffolding of the Vessel Wall. *Tissue Engineering - Part A*, 110306231138043 3.9

45 Coronary Stent Technology. 330-344

44 Moxy<sup>®</sup> drug-coated balloon: a novel device for the treatment of coronary and peripheral vascular disease. *EuroIntervention*, **2011**, 7, 274-7

3.1

43 Drug-Coated Balloons. **2012**, 197-202

42 Bioabsorbable Stents. **2012**, 432-441

41 Local Delivery of Antirestenotic Drugs. *Perspectives in Antisense Science*, **1999**, 153-161

40 A Polymer Coated Cicaprost-Eluting Stent Increases Neointima Formation and Impairs Vessel Function in the Rabbit Iliac Artery. *Pharmacology & Pharmacy*, **2016**, 07, 226-235

0.3

39 Stents: Endovascular. 7586-7600

38 . *Praxis*, **2017**, 106, 85-89

0.1

37 Stents: Endovascular. **2017**, 1465-1479

36 Pathology and Histopathology Evaluations of Biomaterials and Medical Devices. **2019**, 339-400

35 Grafting of Hyaluronic Acid to PLDLA, used as coating of the models of PLLA bioresorbable coronary stents. *The Academic Society Journal*, 302-311

0.1 0

34 Effect of Novel Polymer-Free Nitrogen-Doped Titanium Dioxide Film-Coated Coronary Stent Loaded With Mycophenolic Acid. *Frontiers in Bioengineering and Biotechnology*, **2021**, 9, 650408

5.8 0

33 Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization. *Journal of Visualized Experiments*, **2020**,

1.6 0

32 1990s: Another Move. **2021**, 87-114

31 Coronary Stents and Metal Allergy. **2020**, 1-13

30 2000s: New Field of Focus. **2021**, 127-153

29 Approaches to antithrombotic modification of vascular implants. *Kazan Medical Journal*, **2020**, 101, 232-242

28 Coronary Restenosis. **2005**, 291-308

27	Preclinical Data of Eluting Stents. <b>2007</b> , 333-352		
26	Animal Restenosis Models. <b>2007</b> , 131-150		
25	Developing Drug-Device Combination Products With Unapproved Components. <b>2006</b> , 161-185		
24	Coronary Stents and Metal Allergy. <b>2021</b> , 1171-1183		0
23	REabsorbable vs. DUrable Polymer Drug-Eluting Stents in All-Comer PatiEnts: the REDUCE registry. <i>Coronary Artery Disease</i> , <b>2021</b> , 32, 281-287	1.4	0
22	New advances in endovascular technology. <i>Texas Heart Institute Journal</i> , <b>1997</b> , 24, 156-9	0.8	15
21	Neointimal hyperplasia and endothelial function after percutaneous coronary intervention. <i>Netherlands Heart Journal</i> , <b>2006</b> , 14, 351-353	2.2	
20	Site-specific gene therapy for cardiovascular disease. <i>Current Opinion in Drug Discovery &amp; Development</i> , <b>2010</b> , 13, 203-13		10
19	Controversies in the use & implementation of drug-eluting stent technology. <i>Indian Journal of Medical Research</i> , <b>2012</b> , 136, 926-41	2.9	
18	Percutaneous coronary intervention, a historical perspective looking to the future. <i>Journal of Thoracic Disease</i> , <b>2013</b> , 5, 367-70	2.6	7
17	Poly-l-lactic acid/amorphous calcium phosphate bioabsorbable stent causes less inflammation than poly-l-lactic acid stent in coronary arteries. <i>International Journal of Clinical and Experimental Medicine</i> , <b>2014</b> , 7, 5317-23		5
16	A review of the berberine natural polysaccharide nanostructures as potential anticancer and antibacterial agents.. <i>Biomedicine and Pharmacotherapy</i> , <b>2021</b> , 146, 112531	7.5	1
15	Adventitial histopathological changes after coronary stenting in a porcine model. <i>Veterinarni Medicina</i> , <b>2020</b> , 65, 465-472	0.7	
14	Comparison of biodegradable and newer generation durable polymer drug-eluting stents with short-term dual antiplatelet therapy: a systematic review and Bayesian network meta-analysis of randomized trials comprising of 43,875 patients.. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2022</b> , 53, 671	5.1	1
13	How Does Fluid Flow Influence Drug Release from Drug Filled Implants?. <i>Pharmaceutical Research</i> , <b>2022</b> , 39, 25	4.5	0
12	Target and non-target vessel related events at 10 years post percutaneous coronary intervention.. <i>Clinical Research in Cardiology</i> , <b>2022</b> , 1	6.1	0
11	An implantable Artificial Atherosclerotic Plaque as a Novel Approach for Drug Transport Studies on Drug-eluting Stents. <i>Advanced Healthcare Materials</i> , <b>2021</b> , e2101570	10.1	
10	The Journey of Coronary Stent Technology. <b>2022</b> , 489-496		

9	Successful implantation of a novel polymer-free everolimus-eluting stent using nitrogen-doped titanium dioxide film with good patency on follow-up angiography: A case report. <i>Medicine (United States)</i> , <b>2022</b> , 101, e29666	1.8	○
8	Five-year comparative study of thin-strut rapamycin-eluting bioabsorbable scaffold with metallic drug-eluting stent in porcine coronary artery. <i>Frontiers in Cardiovascular Medicine</i> , 9,	5.4	○
7	Biodegradable Biomaterials in Bone Tissue Engineering. <b>2022</b> , 299-334		○
6	Revealing the corrosion product films of ion-implanted biodegradable ZnCu alloys. <b>2022</b> , 110814		○
5	Drug-Coated Balloon for the Treatment of Small Vessel Coronary Artery Disease [A Randomized Non-Inferiority Trial] <b>2022</b> ,		○
4	Angioscopic Evaluation of Vascular Response After Fluoropolymer-Based Drug-Eluting Stent Implantation for Femoropopliteal Artery Lesions. <b>2023</b> ,		○
3	Paclitaxel exerts antiplatelet and antithrombotic activities: Additional benefit from use of paclitaxel-coated balloons and -eluting stents in coronary revascularization and prevention of in-stent restenosis. <b>2023</b> , 225, 63-72		○
2	Gene Delivery from Stents for Prevention of In-Stent Restenosis. 106-113		○
1	Nanoformulations for cardiovascular therapy. <b>2023</b> , 661-675		○